Associated Papers
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.
Chrisochoidou Y et al.
Blood, 2025
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.
Mejia Saldarriaga M et al.
Frontiers in Oncology, 2022
Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.
Borad MJ et al.
Scientific Reports, 2016
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.
Thakurta A et al.
Leukemia, 2014
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.
Egan JB et al.
British Journal of Haematology, 2013
Select a paper to view details